[go: up one dir, main page]

ECSP078014A - Regimen de dosificacion para prasugrel - Google Patents

Regimen de dosificacion para prasugrel

Info

Publication number
ECSP078014A
ECSP078014A EC2007008014A ECSP078014A ECSP078014A EC SP078014 A ECSP078014 A EC SP078014A EC 2007008014 A EC2007008014 A EC 2007008014A EC SP078014 A ECSP078014 A EC SP078014A EC SP078014 A ECSP078014 A EC SP078014A
Authority
EC
Ecuador
Prior art keywords
prasugrel
dosage regime
dosage
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EC2007008014A
Other languages
English (en)
Inventor
John Thomas Brandt
Nagy Alphonse Farid
Joseph Anthony Jakubowski
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP078014A publication Critical patent/ECSP078014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un régimen de dosificación para tratar la enfermedad vascular en un humano, que comprende las etapas de administrar una dosificación de carga de alrededor de 30 mg hasta 70 mg de dosis de carga de prasugrel o una sal farmacéuticamente aceptable del mismo, y posteriormente administrar un régimen diario de dosificación de alrededor de 7.5 mg a 15 mg de dosis de mantenimiento de prasugrel o una sal farmacéuticamente aceptable del mismo.
EC2007008014A 2005-06-17 2007-12-14 Regimen de dosificacion para prasugrel ECSP078014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ECSP078014A true ECSP078014A (es) 2008-01-23

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008014A ECSP078014A (es) 2005-06-17 2007-12-14 Regimen de dosificacion para prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (es)
EP (1) EP1893205A4 (es)
JP (1) JP2008543853A (es)
KR (1) KR20080016647A (es)
CN (1) CN101198329A (es)
AU (1) AU2006259538A1 (es)
BR (1) BRPI0612624A2 (es)
CA (1) CA2612315A1 (es)
EA (1) EA200800075A1 (es)
EC (1) ECSP078014A (es)
GT (1) GT200600263A (es)
IL (1) IL187486A0 (es)
MA (1) MA29722B1 (es)
MX (1) MX2007015430A (es)
NO (1) NO20080244L (es)
TN (1) TNSN07474A1 (es)
WO (1) WO2006138317A2 (es)
ZA (1) ZA200710769B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5274261B2 (ja) 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
WO2008072532A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 貯蔵安定性が改善された医薬組成物
CN104800210B (zh) 2007-04-27 2019-08-06 锡德克斯药物公司 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
HUE047755T2 (hu) 2009-05-13 2020-05-28 Cydex Pharmaceuticals Inc Prasugrelt és ciklodextrin-származékokat tartalmazó gyógyszerkészítmények, eljárás ezek elõállítására és alkalmazásra
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
DE60134508D1 (de) * 2000-07-06 2008-07-31 Daiichi Sankyo Co Ltd Säure-Additionssalze von Hydropyridinderivaten
CA2432644C (en) * 2000-12-25 2013-07-23 Fumitoshi Asai Pharmaceutical composition comprising aspirintm and cs-747
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
US20060217351A1 (en) * 2003-05-05 2006-09-28 Brandt John T Method for treating cardiovascular diseases

Also Published As

Publication number Publication date
EP1893205A4 (en) 2010-06-30
WO2006138317A2 (en) 2006-12-28
CN101198329A (zh) 2008-06-11
CA2612315A1 (en) 2006-12-28
US20090156632A1 (en) 2009-06-18
KR20080016647A (ko) 2008-02-21
ZA200710769B (en) 2009-09-30
NO20080244L (no) 2008-01-14
IL187486A0 (en) 2008-06-05
EA200800075A1 (ru) 2008-04-28
JP2008543853A (ja) 2008-12-04
MA29722B1 (fr) 2008-09-01
GT200600263A (es) 2007-02-23
BRPI0612624A2 (pt) 2016-11-29
AU2006259538A1 (en) 2006-12-28
MX2007015430A (es) 2008-02-21
WO2006138317A3 (en) 2007-05-03
EP1893205A2 (en) 2008-03-05
TNSN07474A1 (en) 2009-03-17

Similar Documents

Publication Publication Date Title
ECSP078014A (es) Regimen de dosificacion para prasugrel
AR050418A1 (es) Dosificacion fija de anticuerpos her
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
AR048431A1 (es) Formulaciones galenicas de compuestos organicos
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
NO20055880L (no) Memantin orale doseringsformer
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
CL2024001530A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
CL2024001520A1 (es) Nueva composición farmacéutica oral y régimen de dosificación para la terapia de enfermedades pulmonares intersticiales
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno